1. |
News in brief … |
|
Inpharma Weekly,
Volume &NA;,
Issue 1111,
1997,
Page 2-2
&NA;,
Preview
|
PDF (1236KB)
|
|
ISSN:1173-8324
出版商:ADIS
年代:1997
数据来源: ADIS
|
2. |
European peptic ulcer treatment guidelines questioned |
|
Inpharma Weekly,
Volume &NA;,
Issue 1111,
1997,
Page 3-4
Gill Higgins,
Preview
|
PDF (2243KB)
|
|
摘要:
The Maastricht Consensus on the treatment of peptic ulcers recommended the use ofHelicobacter pylorieradication therapy in a wide range of patients with this condition, including those taking NSAIDs.*Professor Chris Hawkey, a leading gastroenterologist from the University of Nottingham, UK, questioned the value of this approach. He said thatH. pylorieradication treatment may even be detrimental to some patients. The issue was debated at the 6th United European Gastroenterology Week [Birmingham, UK; October 1997]. The consequences of mapping theH. pylorigenome for vaccine and drug development were also discussed.
ISSN:1173-8324
出版商:ADIS
年代:1997
数据来源: ADIS
|
3. |
US consensus statement on Alzheimer's disease |
|
Inpharma Weekly,
Volume &NA;,
Issue 1111,
1997,
Page 4-4
&NA;,
Preview
|
PDF (1146KB)
|
|
ISSN:1173-8324
出版商:ADIS
年代:1997
数据来源: ADIS
|
4. |
News in brief … |
|
Inpharma Weekly,
Volume &NA;,
Issue 1111,
1997,
Page 5-5
&NA;,
Preview
|
PDF (1111KB)
|
|
ISSN:1173-8324
出版商:ADIS
年代:1997
数据来源: ADIS
|
5. |
Tiludronic acidvsetidronic acid for Paget's disease of the bone |
|
Inpharma Weekly,
Volume &NA;,
Issue 1111,
1997,
Page 6-6
&NA;,
Preview
|
PDF (1131KB)
|
|
ISSN:1173-8324
出版商:ADIS
年代:1997
数据来源: ADIS
|
6. |
News in brief … |
|
Inpharma Weekly,
Volume &NA;,
Issue 1111,
1997,
Page 7-7
&NA;,
Preview
|
PDF (1018KB)
|
|
ISSN:1173-8324
出版商:ADIS
年代:1997
数据来源: ADIS
|
7. |
5-Aminolevulinic acid effective in actinic keratoses |
|
Inpharma Weekly,
Volume &NA;,
Issue 1111,
1997,
Page 8-8
&NA;,
Preview
|
PDF (1115KB)
|
|
ISSN:1173-8324
出版商:ADIS
年代:1997
数据来源: ADIS
|
8. |
Phosphodiesterase inhibitors: the next generation |
|
Inpharma Weekly,
Volume &NA;,
Issue 1111,
1997,
Page 9-10
Wayne Elwood,
Preview
|
PDF (2249KB)
|
|
摘要:
Phosphodiesterase type IV (PDE IV) inhibitors have wide ranging anti-inflammatory effects which have given rise to the concept that they may be useful in the treatment of asthma and other respiratory disorders. The first generation of PDE IV inhibitors, such as rolipram, had profound anti-inflammatory effects, but their clinical use was limited by their class-associated adverse effects which were caused by inhibition of PDE IV in nontarget tissues. The aim of the pharmaceutical industry has been to improve this pharmacological profile with a new generation of compounds that retain the anti-inflammatory effects of the first-generation inhibitors, but which also possess an improved therapeutic index. SB-207499 [SmithKline Beecham; phase II] is the most advanced of these second-generation PDE IV inhibitors. The preclinical pharmacology of this exciting new compound was discussed at the Annual Congress of the European Respiratory Society [Berlin, Germany; September 1997].
ISSN:1173-8324
出版商:ADIS
年代:1997
数据来源: ADIS
|
9. |
News in brief … |
|
Inpharma Weekly,
Volume &NA;,
Issue 1111,
1997,
Page 10-10
&NA;,
Preview
|
PDF (1164KB)
|
|
ISSN:1173-8324
出版商:ADIS
年代:1997
数据来源: ADIS
|
10. |
News in brief … |
|
Inpharma Weekly,
Volume &NA;,
Issue 1111,
1997,
Page 11-11
&NA;,
Preview
|
PDF (1060KB)
|
|
ISSN:1173-8324
出版商:ADIS
年代:1997
数据来源: ADIS
|